Global Vision Loss Research

Focus: Replacing or repairing damaged retinal cells, including retinal pigment epithelium (RPE) cells and photoreceptors.

Stem cell research aims to regenerate retinal tissue using embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs). Early-phase clinical trials are underway in several countries, including Japan and the United States.

While some studies have shown encouraging signs of retinal integration and partial visual improvement, stem cell therapies for retinal disease remain experimental. Long-term safety, effectiveness, and accessibility still require further research before widespread clinical use becomes possible.

Gene-based treatments require an accurate genetic diagnosis, which is why genetic testing and counselling play a crucial role in retinal research and future treatment access. Retina South Africa can facilitate this.

Gene Replacement Therapy

Focus: Delivering a healthy copy of a gene to retinal cells using viral vectors such as adeno-associated viruses (AAVs).

Gene replacement therapies are most effective for certain single-gene inherited retinal conditions. To date, more than 200 gene therapy trials have been initiated globally. One approved example  is Luxturna for the RPE65 form of Leber Congenital Amaurosis [LCA]

These therapies are highly gene-specific and currently very costly, meaning access remains limited for many patients worldwide.

Further research and clinical trial information

These resources are provided for information only and do not indicate eligibility or availability.

For those who wish to explore ongoing gene therapy research in more detail, trusted sources include.

• ClinicalTrials.gov [External Link] – a global registry of publicly and privately funded clinical studies
• Fightingblindness.org [External Link] – Research Pipeline – accessible summaries of retinal research and clinical trial developments

Retina South Africa encourages individuals to discuss any trial information with a qualified healthcare professional or genetic counsellor before taking further steps.

Gene Editing

Focus: Correcting or modifying faulty genetic material using technologies such as CRISPR-based editing or RNA editing.

Gene editing research aims to address genetic errors at their source. While this field holds significant promise, most retinal gene-editing treatments are still in early clinical trial phases and are not yet available outside research settings.

Pharmaceutical research focuses on developing medications that may slow the progression of vision loss, rather than cure retinal conditions. These treatments include antioxidants, inhibitors, modulators, and small-molecule therapies.

Pharmaceutical research also plays an important role in managing diabetic vision loss, with ongoing studies focused on reducing inflammation, vascular damage, and disease progression associated with diabetes-related eye conditions.

Retinal implants aim to restore partial vision using electronic devices that stimulate remaining retinal or neural cells.

One example is the PRIMA system, which has been studied in Europe for advanced dry age-related macular degeneration (AMD). This technology involves implanting a microchip beneath the retina, which works alongside external visual processing devices.

While some participants have experienced improvements in reading large print or navigating environments, extensive training is required, and costs remain a major barrier. Artificial vision technologies continue to evolve but are not suitable for all types of vision loss.

Next-generation retinal implants are also under active development. Researchers are exploring implants with higher resolution, more powerful processing capabilities, and enhanced features such as zoom and infrared sensitivity. Ongoing studies focus on improving implant design, refining surgical techniques, and enhancing functional vision outcomes for people with conditions such as retinitis pigmentosa and age-related macular degeneration (AMD).

Optogenetic research involves introducing light-sensitive proteins into surviving retinal cells to restore light perception. Several clinical trials are currently exploring this approach for advanced retinal degeneration, including retinitis pigmentosa.

Early results suggest potential improvements in light sensitivity and functional vision in controlled environments. However, optogenetic treatments remain experimental and require further study before broader availability.

Research into nutrition and retinal degeneration examines how diet and supplementation may support eye health alongside medical care.

Studies such as AREDS2 have shown that certain antioxidant combinations may benefit people with intermediate AMD. Nutrients including lutein, zeaxanthin, omega-3 fatty acids, and glutathione continue to be studied for their potential supportive role.

Importantly, nutritional interventions are considered adjuncts, not cures, and should always be discussed with healthcare professionals.

Alongside medical research, assistive technologies play a vital role in improving independence and quality of life for people living with vision loss.

These include:

• Screen readers and voice-activated tools
• Adjustable magnification software
• Smartphone accessibility features
• Wearable devices such as smart glasses and watches

Many of these tools are affordable, widely available, and adaptable to individual needs. Retina South Africa’s counsellors support individuals in accessing assistive technologies, mobility services, low-vision rehabilitation, and peer support.

Retina South Africa plays a vital role in helping individuals and families navigate the rapidly changing landscape of retinal research. This includes:

• Supporting access to genetic testing and counselling
• Sharing accurate, ethical research updates
• Assisting with clinical trial awareness
• Providing psychosocial support and practical guidance

We work to ensure that hope is grounded in evidence, transparency, and compassion.